Levels of follicle stimulating hormone (FSH), luteinizing hormone (LH) and testosterone were assessed by electrohemiluminiscence immunoassay. Normal learn more values of our laboratory are 1.5-12.4 mlU/l for FSH, 1.7-8.6 mlU/l for LH and 8.64-29.0 nmol/l for testosterone. Regarding interstitial testicular function, patients with normal values of LH and testosterone were classified as eugonadic, those with increased LH and normal testosterone had compensated hypogonadism and those with Inhibitors,research,lifescience,medical increased LH and decreased testosterone had primary hypogonadism. Increased level of FSH indicated tubular failure of testicles. All patients completed Serbian version

of the SF-36 questionnaire as a measure of health-related QoL (12). The SF-36 is a generic instrument that measures eight general health concepts: physical functioning (PF), role physical (RP), bodily pain (BP), general health Inhibitors,research,lifescience,medical (GH), vitality (VT), social functioning (SF), role emotional (RE) and mental health (MH). Two main scores are available to summarize these scales: physical composite

score (PCS) and mental composite score (MCS), as well Inhibitors,research,lifescience,medical as total SF- 36 score. All these scores fall within a 0-100 scale. Higher scores reflect better HRQoL. Methods of descriptive statistic, χ2 test for comparisons between nominal and ordinal variables and Mann- Withney U test for comparisons between continous nonparametric variables were used. In all analyses, Inhibitors,research,lifescience,medical significant testing was two-sided, with alpha set at 0.05 for statistical significance and 0.01 for high statistical significance. Results Demographic and clinical characteristics of the patients are shown in Table 1. Table 1. Demographic and clinical features of investigated men with DM1 (n = 25). Mean IIEF-5 score was 16.4 ± 6.2. Eighteen (72%) patients had ED. Mild ED was Inhibitors,research,lifescience,medical detected in 8 patients (32%), mild to moderate in 4 (16%), moderate in 3 (12%) and severe ED in 3 patient (12%). Mean testosterone level in our DM1 patients was within normal range (16.8

± 6.5 nmol/l), while mean LH and FSH levels were increased (11.5 ± 4.4 mlU/l and 22.7 ± 14.7 mlU/l, respectively). Seven (28%) patients were eugonadic, 16 (64%) had compensated hypogonadism and 2 (8%) patients had primary hypogonadism. Increased FSH, index of tubular Vasopressin Receptor dysfunction, was registered in 15 (60%) patients and it was more frequent in DM1 men with androgenic dysfunction (88% vs. 20%, p < 0.01). Comparisons of different demographic and clinical features between patients with and without ED are presented in Table 2. Presence of ED was not in association with age at the onset of disease, age at the moment of investigation, duration of disease, number of CTG repeats and degree of muscle weakness. Difference in the hormones levels was not observed between patients with and without ED.